PortfoliosLab logoPortfoliosLab logo
VRNA vs. PSIX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

VRNA vs. PSIX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Verona Pharma plc (VRNA) and Power Solutions International, Inc. (PSIX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


VRNA

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*

PSIX

1D
5.96%
1M
-47.50%
YTD
-30.26%
6M
-33.00%
1Y
-16.09%
3Y*
158.76%
5Y*
56.83%
10Y*
9.24%
*Multi-year figures are annualized to reflect compound growth (CAGR)

VRNA vs. PSIX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
VRNA
Verona Pharma plc
0.00%130.21%133.60%-23.92%288.84%-4.00%21.74%-40.41%-18.71%-12.07%
PSIX
Power Solutions International, Inc.
-30.26%92.07%1,351.22%-31.67%0.00%-9.09%-58.23%-14.59%23.33%-2.98%

Correlation

The correlation between VRNA and PSIX is -0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.03

Correlation (3Y)
Calculated over the trailing 3-year period

0.08

Correlation (5Y)
Calculated over the trailing 5-year period

0.05

Correlation (All Time)
Calculated using the full available price history since Apr 27, 2017

0.05

The correlation between VRNA and PSIX shifts across timeframes, from -0.03 (1 year) to 0.08 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

VRNA:

$9.72B

PSIX:

$919.06M

EPS

VRNA:

-$0.69

PSIX:

$4.43

PS Ratio

VRNA:

57.97

PSIX:

1.57

PB Ratio

VRNA:

34.92

PSIX:

4.95

Total Revenue (TTM)

VRNA:

$167.65M

PSIX:

$586.96M

Gross Profit (TTM)

VRNA:

$159.52M

PSIX:

$172.81M

EBITDA (TTM)

VRNA:

-$40.86M

PSIX:

$102.78M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

VRNA vs. PSIX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VRNA

PSIX
PSIX Risk / Return Rank: 3838
Overall Rank
PSIX Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
PSIX Sortino Ratio Rank: 4444
Sortino Ratio Rank
PSIX Omega Ratio Rank: 4444
Omega Ratio Rank
PSIX Calmar Ratio Rank: 3535
Calmar Ratio Rank
PSIX Martin Ratio Rank: 3434
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VRNA vs. PSIX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and Power Solutions International, Inc. (PSIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

VRNA vs. PSIX - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


VRNAPSIXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.16

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.50

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.09

Sharpe Ratio (All Time)

Calculated using the full available price history

0.06

Drawdowns

VRNA vs. PSIX - Drawdown Comparison


Loading charts...

Drawdown Indicators


VRNAPSIXDifference

Max Drawdown

Largest peak-to-trough decline

-98.55%

Max Drawdown (1Y)

Largest decline over 1 year

-68.60%

Max Drawdown (3Y)

Largest decline over 3 years

-68.60%

Max Drawdown (5Y)

Largest decline over 5 years

-84.37%

Max Drawdown (10Y)

Largest decline over 10 years

-93.77%

Current Drawdown

Current decline from peak

-65.58%

Average Drawdown

Average peak-to-trough decline

-68.23%

Ulcer Index

Depth and duration of drawdowns from previous peaks

36.00%

Volatility

VRNA vs. PSIX - Volatility Comparison


Loading charts...

Volatility by Period


VRNAPSIXDifference

Volatility (1M)

Calculated over the trailing 1-month period

60.17%

Volatility (6M)

Calculated over the trailing 6-month period

89.62%

Volatility (1Y)

Calculated over the trailing 1-year period

103.20%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

113.43%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

105.98%

Dividends

VRNA vs. PSIX - Dividend Comparison

Neither VRNA nor PSIX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

VRNA vs. PSIX - Financials Comparison

This section allows you to compare key financial metrics between Verona Pharma plc and Power Solutions International, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
75.14M
0
(VRNA) Total Revenue
(PSIX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


VRNA and PSIX have a correlation of -0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for VRNA and PSIX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer